… Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …

… type of lung cancer is non‐small cell lung cancer (NSCLC). … kind of cancer known as epidermal
growth factor receptor … in the cancer cells to the genes controlling tumour growth. In this …

… Lung cancer is the leading cause of cancer-related mortality globally, … lung cancer (NSCLC)
is the most common type of lung cancer, accounting for approximately 80–90% of all lung …

… Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in advanced
EGFR-mutant non–small-cell lung cancer (NSCLC), we tested adjuvant erlotinib in patients with …

… , lung cancer is the most common cause of cancer-related death worldwide.[ 1 ] According to
the GLOBOCAN report 2018, the estimated incidence of lung cancer … third in cancer-related …

… Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with cytotoxic
chemotherapy is highly effective for the treatment of advanced non–small-cell lung cancer (…

… Mutations in the epidermal growth factor receptor (EGFR) gene are the most … cell lung
cancer (NSCLC), occurring in approximately 50% and 10–15% of adenocarcinomas of the lung in …

… of patients with advanced non–small-cell lung cancer (NSCLC). The incidence of LM rises
to approximately 9% in epidermal growth factor receptor-mutated (EGFRm) NSCLC. Survival …

… with epidermal growth factor receptor (EGFR)–mutated non–small-cell lung cancer (NSCLC). …
For patients with epidermal growth factor receptor (EGFR)–mutated advanced non–small-…

… cell lung cancer and small cell lung cancer (C). Kaplan-Meier survival analysis according
to FGFR1 gene amplification in squamous cell lung cancer (D) and small cell lung cancer …